RSS Feeds
The Sweet Syndrome during Therapy with Granulocyte Colony-stimulating Factor
- John W. Park, MD;
- Bhoomi Mehrotra, MD;
- Bryan O. Barnett, MD;
- Ari D. Baron, MD; and
- Alan P. Venook, MD
Excerpt
Granulocyte colony-stimulating factor (G-CSF; filgrastim), a hematopoietic growth factor that promotes the proliferation and differentiation of neutrophils, is an important new adjunct to cancer chemotherapy. It is effective in lessening the degree and duration of neutropenia and is usually well tolerated. We report a case of the Sweet syndrome that developed during G-CSF therapy in a woman with breast cancer who was undergoing chemotherapy.
Case Report A 41-year-old woman receiving chemotherapy and G-CSF therapy for breast cancer presented with acute fever and skin rash. Except for recently diagnosed breast cancer, her medical history was unremarkable. The diagnosis of breast cancer
Article and Author Information
-
From the University of California, San Francisco, San Francisco, California. For current author addresses, see end of text.
-
Requests for Reprints: John W. Park, MD, Hematology/Oncology Clinic, Ambulatory Care Center A-502, 400 Parnassus Avenue, University of California, San Francisco, San Francisco, CA 94143-0324.
-
Current Author Addresses: Drs. Park, Mehrotra, Baron, and Venook: Division of Hematology/Oncology, 400 Parnassus Avenue, University of California, San Francisco, San Francisco, CA 94143-0324.
Dr. Barnett: Department of Dermatology, 400 Parnassus Avenue, University of California, San Francisco, San Francisco, CA 94143-0324.
